Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - dobutamine hydrochloride, quantity: 14.01 mg/ml (equivalent: dobutamine, qty 12.5 mg/ml) - injection, concentrated - excipient ingredients: sodium metabisulfite; water for injections; hydrochloric acid; sodium hydroxide - dobutamine is indicated for adults who require inotropic support in the treatment of low output cardiac failure associated with organic heart disease, myocardial infarction, open heart surgery, cardiomyophathies, septic shock and cardiogenic shock. dobutamine can increase or maintain cardiac output during positive end expiratory pressure ventilation.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dobutamine hydrochloride 12.5 mg/ml - solution for injection - 12.5 mg/ml - active: dobutamine hydrochloride 12.5 mg/ml excipient: sodium metabisulfite water for injection - dobutamine hydrochloride is indicated when inotropic support is necessary for the treatment of patients with hypoperfusion states in whom cardiac output is insufficient to meet circulatory demands. dobutamine hydrochloride is also indicated when inotropic support is required for the treatment of patients in whom abnormally increased ventricular filling pressures introduce the risk of pulmonary congestion and oedema. (refer to the data sheet for conditions which may precipitate such situations).

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - linezolid, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: sodium citrate; sodium hydroxide; glucose monohydrate; citric acid; hydrochloric acid; water for injections - linezolid is indicated for the treatment of suspected or proven infections due to gram-positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - linezolid, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: hydrochloric acid; sodium citrate; citric acid; sodium hydroxide; water for injections; glucose monohydrate - linezolid is indicated for the treatment of suspected or proven infections due to gram-positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - esmolol hydrochloride, quantity: 2500 mg - injection, powder for - excipient ingredients: - supraventricular tachycardia,brevibloc (esmolol hcl) is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. brevibloc is also indicated in non compensatory sinus tachycardia where, in the physician's judgement, the rapid heart rate requires specific intervention. brevibloc is not intended for use in chronic settings where transfer to another agent is anticipated or for treatment periods greater than 24 hours duration.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

rex medical ltd - dobutamine hydrochloride 14.01 mg/ml equivalent to dobutamine 12.5 mg/ml;   - concentrate for infusion - 250 mg/20ml - active: dobutamine hydrochloride 14.01 mg/ml equivalent to dobutamine 12.5 mg/ml   excipient: hydrochloric acid sodium hydroxide sodium metabisulfite water for injection - dobutamine is indicated when inotropic support is necessary for the treatment of patients with hypoperfusion states in whom cardiac output is insufficient to meet circulatory demands. dobutamine is also indicated when inotropic support is required for the treatment of patients in whom abnormally increased ventricular filling pressures introduce the risk of pulmonary congestion and oedema. conditions which may precipitate such situations include the following hypoperfusion states: initially cardiac in origin a. acute heart failure 1. acute myocardial infarction 2. cardiogenic shock 3. following cardiac surgery 4. medicine-induced depression of cardiac contractility such as that which occurs in excessive ?- adrenergic receptor blockade. b. chronic heart failure 1. acute decompensation of chronic congestive heart failure 2. temporary inotropic support in advanced chronic congestive heart failure, as an adjunct to therapy with conventional oral inotropic agents, systemic vasodilators, and diuretics. initially noncardiac in origin 1. acute hypoperfusion states secondary to trauma, surgery, sepsis, or hypovolaemia when mean arterial pressure is above 70-mm hg and pulmonary capillary wedge pressure is 18-mm hg or greater, with inadequate response to volume repletion and increased ventricular filling pressure 2. low cardiac output secondary to mechanical ventilation with positive end-expiratory pressure (peep). dobutamine is indicated in all paediatric age groups (from neonates to 18 years of age) as inotropic support in low cardiac output hypoperfusion states resulting from decompensated heart failure, following cardiac surgery, cardiomyopathies and in cardiogenic or septic shock.

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - dobutamine hydrochloride - concentrate for soln for inf - 12.5 mg/ml

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

hameln pharmaceuticals gmbh - dobutamine hydrochloride - concentrate for soln for inf - 12.5 mg/ml

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

hameln pharmaceuticals gmbh - dobutamine hydrochloride - concentrate for soln for inf - 50 mg/ml

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

viatris limited - dobutamine hydrochloride 56.05mg equivalent to dobutamine 50 mg - concentrate for infusion - 50 mg/ml - active: dobutamine hydrochloride 56.05mg equivalent to dobutamine 50 mg excipient: ascorbic acid water for injection - dobutamine hydrochloride is indicated when inotropic support is necessary for the treatment of patients with hypoperfusion states in whom cardiac output is insufficient to meet circulatory demands. dobutamine hydrochloride is also indicated when inotropic support is required for the treatment of patients in whom abnormally increased ventricular filling pressures introduce the risk of pulmonary congestion and oedema. conditions which may precipitate such situations include the following hypoperfusion states: initially cardiac in origin a. acute heart failure 1. acute myocardial infarction 2. cardiogenic shock 3. following cardiac surgery 4. medicine-induced depression of cardiac contractility such as that which occurs in excessive beta-adrenergic receptor blockade. b. chronic heart failure 1. acute decompensation of chronic congestive heart failure 2. temporary inotropic support in advanced chronic congestive heart failure, as an adjunct to therapy with conventional oral inotropic agents, systemic vasodilators, and diuretics. initially non-cardiac in origin 1. acute hypoperfusion states secondary to trauma, surgery, sepsis, or hypovolaemia when mean arterial pressure is above 70-mm hg and pulmonary capillary wedge pressure is 18-mm hg or greater, with inadequate response to volume repletion and increased ventricular filling pressure 2. low cardiac output secondary to mechanical ventilation with positive end-expiratory pressure (peep). dobutamine hydrochloride may be used as a substitute for physical exercise in stress testing in the diagnosis of coronary artery disease. when dobutamine hydrochloride is used for this purpose, as is the case when exercise is used for stress testing, patients should be informed of the potential risks involved in the test. in addition, patients should be subjected to the same close monitoring that is mandatory in standard exercise stress tests, including continuous electrocardiographic monitoring.